|

Relatlimab Clinical Trials

8 actively recruiting trials across 7 locations

No change since May 2026

Also known as: BMS 986016, BMS-986016, BMS-986016-01, BMS986016, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer +1 more

Pipeline

Phase 2: 5Phase 3: 1Phase 4: 1Phase 2/3: 1

Top Sponsors

  • National Cancer Institute (NCI)2
  • Bristol-Myers Squibb2
  • The Netherlands Cancer Institute1
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
  • NYU Langone Health1

Indications

  • Cancer8
  • Stage IV Bladder Urothelial Carcinoma AJCC v71
  • Stage III Bladder Urothelial Carcinoma AJCC v6 and v71
  • Stage II Bladder Urothelial Carcinoma AJCC v6 and v71
  • Muscle Invasive Urethral Urothelial Carcinoma1

Other1 trial

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
Phase 2

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Mobile, Alabama1 trial

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Local Institution - 0487

Phase 3

Phoenix, Arizona1 trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Cancer Center at Saint Joseph's

Phase 2/3

Dublin, California1 trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Kaiser Permanente Dublin

Phase 2

Baltimore, Maryland1 trial

Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma

Johns Hopkins Hospital

Phase 2

New York, New York1 trial

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

NYU Langone Health

Phase 4

Houston, Texas1 trial

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

M D Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.